Printer Friendly

Dutch court upholds Immunomedics' patent

Immunomedics, Inc. (Morris Plains, NJ; 973-605-8200) announced that the nullification claim made in the Netherlands against its European patent was dismissed by the District Court in The Hague. The patent involved covers a class of CEA-specific antibodies and other related subject matter. The court upheld all of the patent's claims.

Immunomedics also announced that it has granted a royalty-bearing, non-exclusive license to Dako AS (Glostrup, Denmark), a company selling reagents for diagnostic pathology worldwide, for Immunomedics' worldwide patents covering specific antibodies to CEA. This antibody is being sold by DAKO worldwide for use in pathology laboratories that stain tumor specimens for CEA. Terms of the license were not disclosed.

"One of Immunomedics' greatest assets is its broad patent portfolio," explained the company's president and chief executive officer, Mr. Robert J. DeLuccia. "We believe there is considerable value in many of these patents that have been awarded in major geographic markets. Accordingly, we have begun to contact potential licensees in order to offer non-exclusive licenses consistent with our strategy to aggressively pursue enforcement of our patent rights," he added.

In addition to patents covering certain antibodies, including reengineered forms, Immunomedics holds numerous broad patents in the area of disease targeting, imaging and therapy (including cancer, infectious and cardiovascular diseases), radiolabeled antibodies and fragments, pre-targeting methods for imaging and therapy, neutron-capture therapy of cancer, intraoperative and laparoscopic probe technology with radioimaging agents, magnetic-resonance imaging with specific antibodies, positron-emission tomography with specific antibodies, radioimmunotherapy with anti-idiotype antibodies and other vaccine approaches.

"These areas may afford us diverse licensing and partnering opportunities," Mr. DeLuccia stated.

Immunomedics is a biopharmaceutical company focused on the development, manufacture and commercialization of diagnostic imaging and therapeutic products for the detection and treatment of cancer and infectious diseases. Integral to these products are highly specific monoclonal antibodies and antibody fragments designed to deliver radioisotopes and chemotherapeutic agents to tumors and sites of infection. The company's first product, CEA-Scan for the detection of colorectal cancer, has been approved in the United States, Canada, and Europe. The company's second diagnostic imaging product, LeukoScan, has been approved for sale in Europe for the diagnosis of osteomyelitis (bone infection). This product is presently under regulatory review by the United States Food and Drug Administration. Immunomedics also has several other diagnostic imaging products and two therapeutic products in clinical trials.
COPYRIGHT 1998 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1998 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:BIOTECH Patent News
Article Type:Article
Geographic Code:1USA
Date:Jul 1, 1998
Words:386
Previous Article:OraVax receives United States patent for the use of a protein to detect highly virulent strains of Helicobacter pylori
Next Article:United States Judge grants Biochem's motion to say 3TC patent case
Topics:


Related Articles
Immunomedics defeats Hoffmann-LaRoche patent challenge and an opposition in Japan.
Immunomedics awarded two United States patents for therapeutic radiopharmaceuticals.
Novartis wins favorable decision against American Home Products in patent infringement action against Certican.
Patent on positron emission tomography agents awarded to Immunomedics.
Immunomedics granted patent for Cd22 antibodies in lymphoma therapies.
Medix licenses Immunomedics' carcinoembryonic antigen technology.
Immunomedics to appeal tumor detection patent infringement decision.
Dutch Supreme Court sustains Immunomedics patent.
Boston Scientific and Angiotech win patent infringement case against Conor in the Netherlands court orders injunction and damages.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters